APA (7th ed.) Citation

C, F., J, Y., Y, P., J, H., M, C., R, L., . . . G, L. (2026). Addition of rituximab to CEAC conditioning for autologous hematopoietic stem cell transplantation provides no survival benefit in diffuse large B-Cell lymphoma: A propensity score-matched cohort study. Annals of hematology, 105(2), 71. https://doi.org/10.1007/s00277-026-06834-3

Chicago Style (17th ed.) Citation

C, Fan, et al. "Addition of Rituximab to CEAC Conditioning for Autologous Hematopoietic Stem Cell Transplantation Provides No Survival Benefit in Diffuse Large B-Cell Lymphoma: A Propensity Score-matched Cohort Study." Annals of Hematology 105, no. 2 (2026): 71. https://doi.org/10.1007/s00277-026-06834-3.

MLA (9th ed.) Citation

C, Fan, et al. "Addition of Rituximab to CEAC Conditioning for Autologous Hematopoietic Stem Cell Transplantation Provides No Survival Benefit in Diffuse Large B-Cell Lymphoma: A Propensity Score-matched Cohort Study." Annals of Hematology, vol. 105, no. 2, 2026, p. 71, https://doi.org/10.1007/s00277-026-06834-3.